USD 7.98
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| OCUL | -0.1 | -2.1 | -6.8 | -26.5 | -0.9 | 92.8 | 41.0 | 70.1 | -69.7 | -39.3 |
| S&P 500 | -0.1 | 1.4 | 1.8 | 4.9 | 9.5 | 25.0 | 37.9 | 82.9 | 196.4 | 34336.4 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | OCUL |
| name | Ocular Therapeutix, Inc. |
| price | 7.98 |
| changes percentage | -0.1252 |
| change | -0.01 |
| day low | 7.91 |
| day high | 7.99 |
| year high | 11.775 |
| year low | 4.06 |
| market cap | 1254591660 |
| price avg 50 | 9.0412 |
| price avg 200 | 8.07745 |
| exchange | NASDAQ |
| volume | 41579 |
| avg volume | 892815 |
| open | 7.91 |
| previous close | 7.99 |
| eps | -1.29 |
| pe | -6.19 |
| earnings announcement | 2025-03-10T10:59:00.000+0000 |
| shares outstanding | 157217000 |
| timestamp | 2025-01-23 15:25:03 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001393434 | |||
| revenue | 58443000 | 51494000 | 13.49 |
| gross profit | 53162000 | 46954000 | 13.22 |
| gross profit ratio | 0.91 | 0.91 | -0.24 |
| research and development expenses | 61055000 | 53462000 | 14.20 |
| operating expenses | 135544000 | 125608000 | 7.91 |
| interest income | 3983000 | 798000 | 399.12 |
| interest expense | 11338000 | 7022000 | 61.46 |
| ebitda | -66415000 | -61907000 | -7.28 |
| ebitdaratio | -1.14 | -1.51 | 24.84 |
| operating income | -82382000 | -78654000 | -4.74 |
| operating income ratio | -1.41 | -1.53 | 7.71 |
| net income | -80736000 | -63422000 | -27.30 |
| net income ratio | -1.38 | -1.23 | -12.16 |
| eps | -1.09 | -0.83 | -31.33 |
Revenue Growth: revenue increased to 58 million in 2023 from 51 million in 2022 representing a change of 13.49%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 53 million in 2023 from 47 million in 2022 representing a change of 13.22%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 61 million in 2023 from 53 million in 2022 representing a change of 14.2%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -66 million in 2023 from -62 million in 2022 representing a change of -7.28%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -82 million in 2023 from -79 million in 2022 representing a change of -4.74%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -81 million in 2023 from -63 million in 2022 representing a change of -27.3%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Operating Expenses: Operating Expenses increased to 136 million in 2023 from 126 million in 2022 representing a change of 7.91%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Earnings per Share (EPS): EPS increased to -1.09 in 2023 from -1.09 in 2022 representing a change of -31.33%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001393434 | |||
| revenue | 15425000 | 16440999 | -6.18 |
| gross profit | 13864000 | 14931999 | -7.15 |
| gross profit ratio | 0.9 | 0.91 | -1.04 |
| research and development expenses | 37054000 | 28857000 | 28.41 |
| operating expenses | 59862000 | 58522000 | 2.29 |
| interest income | 5653000 | 6036000 | -6.35 |
| interest expense | 3224000 | 3196000 | 0.88 |
| ebitda | -32310000 | -39625000 | 18.46 |
| ebitdaratio | -2.09 | -2.41 | 13.09 |
| operating income | -45998000 | -43590000 | -5.52 |
| operating income ratio | -2.98 | -2.65 | -12.47 |
| net income | -36493000 | -43777000 | 16.64 |
| net income ratio | -2.37 | -2.66 | 11.15 |
| eps | -0.22 | -0.26 | 15.38 |
Revenue Growth: revenue decreased to 15 million in 2024Q3 from 16 million in 2024Q2 representing a change of -6.18%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to 14 million in 2024Q3 from 15 million in 2024Q2 representing a change of -7.15%. This indicates a sales profitability decline, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 60 million in 2024Q3 from 59 million in 2024Q2 representing a change of 2.29%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -32 million in 2024Q3 from -40 million in 2024Q2 representing a change of 18.46%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Net Income: Net income decreased to -36 million in 2024Q3 from -44 million in 2024Q2 representing a change of 16.64%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Research and Development (R&D) Expenses: R&D Expenses increased to 37 million in 2024Q3 from 29 million in 2024Q2 representing a change of 28.41%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Operating Income: Operating income increased to -46 million in 2024Q3 from -44 million in 2024Q2 representing a change of -5.52%. The increase in operating income indicates better operational performance and increased profitability.
Earnings per Share (EPS): EPS increased to -0.22 in 2024Q3 from -0.22 in 2024Q2 representing a change of 15.38%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001393434 | |||
| total assets | 252060000 | 149289000 | 68.84 |
| total liabilities | 160929000 | 113910000 | 41.28 |
| total equity | 91131000 | 35379000 | 157.59 |
| cash and cash equivalents | 195807000 | 102300000 | 91.40 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 1764000 | -100.00 |
| total current assets | 232235000 | 129627000 | 79.16 |
| total non current assets | 19825000 | 19662000 | 0.83 |
| total current liabilities | 34896000 | 31395000 | 11.15 |
| total non current liabilities | 126033000 | 82515000 | 52.74 |
| common stock | 12000 | 8000 | 50.00 |
| retained earnings | -697578000 | -616842000 | -13.09 |
| total debt | 83389000 | 64283000 | 29.72 |
Total Assets: Total Assets increased to 252 million in 2023 from 149 million in 2022 representing a change of 68.84%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 91 million in 2023 from 35 million in 2022 representing a change of 157.59%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 196 million in 2023 from 102 million in 2022 representing a change of 91.4%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 232 million in 2023 from 130 million in 2022 representing a change of 79.16%. This indicates a better liquidity position.
Common Stock: Common Stock increased to 0 in 2023 from 0 in 2022 representing a change of 50.0%. This indicates an increase in ownership interest.
Total Liabilities: Total Liabilities increased to 161 million in 2023 from 114 million in 2022 representing a change of 41.28%. This indicates an increase in overall liabilities.
Total Current Liabilities: Total Current Liabilities increased to 35 million in 2023 from 31 million in 2022 representing a change of 11.15%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -698 million in 2023 from -617 million in 2022 representing a change of -13.09%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 83 million in 2023 from 64 million in 2022 representing a change of 29.72%. This indicates an increase in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001393434 | |||
| total assets | 490369000 | 517091000 | -5.17 |
| total liabilities | 138348000 | 139396000 | -0.75 |
| total equity | 352021000 | 377695000 | -6.80 |
| cash and cash equivalents | 427220000 | 459690000 | -7.06 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 473011000 | 498585000 | -5.13 |
| total non current assets | 17358000 | 18506000 | -6.20 |
| total current liabilities | 36359000 | 29972000 | 21.31 |
| total non current liabilities | 101989000 | 109424000 | -6.79 |
| common stock | 16000 | 16000 | 0.00 |
| retained earnings | -842696000 | -806203000 | -4.53 |
| total debt | 75124000 | 74888000 | 0.32 |
Total Assets: Total Assets decreased to 490 million in 2024Q3 from 517 million in 2024Q2 representing a change of -5.17%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 352 million in 2024Q3 from 378 million in 2024Q2 representing a change of -6.8%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 427 million in 2024Q3 from 460 million in 2024Q2 representing a change of -7.06%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 473 million in 2024Q3 from 499 million in 2024Q2 representing a change of -5.13%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 36 million in 2024Q3 from 30 million in 2024Q2 representing a change of 21.31%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -843 million in 2024Q3 from -806 million in 2024Q2 representing a change of -4.53%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 75 million in 2024Q3 from 75 million in 2024Q2 representing a change of 0.32%. This indicates an increase in overall debt burden.
Total Liabilities: Total Liabilities decreased to 138 million in 2024Q3 from 139 million in 2024Q2 representing a change of -0.75%. This indicates a decrease in overall liabilities.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001393434 | |||
| net change in cash | 93507000 | -61864000 | 251.15 |
| operating cash flow | -70234000 | -59603000 | -17.84 |
| free cash flow | -76321000 | -63318000 | -20.54 |
| capital expenditure | -6087000 | -3715000 | -63.85 |
| depreciation and amortization | 2983000 | 2109000 | 41.44 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 17825000 | 16964000 | 5.08 |
| accounts payables | 583000 | -621000 | 193.88 |
| inventory | -331000 | -724000 | 54.28 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -6087000 | -3715000 | -63.85 |
| net cash used for investing activites | -6087000 | -3715000 | -63.85 |
| debt repayment | 56349000 | 0 | NaN |
| common stock issued | 117261000 | 1454000 | 7964.72 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 169828000 | 1454000 | 11580.06 |
| cash at end of period | 197571000 | 104064000 | 89.86 |
| accounts receivables | -4854000 | -190000 | -2454.74 |
| cash at beginning of period | 104064000 | 165928000 | -37.28 |
Net Change in Cash: Net Change in Cash increased to 94 million in 2023 from -62 million in 2022 representing a change of 251.15%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Capital Expenditure: Capital Expenditure decreased to -6 million in 2023 from -4 million in 2022 representing a change of -63.85%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Accounts Payables: The absolute value of Accounts Payables decreased to 1 million in 2023 from 1 million in 2022 representing a change of 193.88%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables decreased to -5 million in 2023 from 0 million in 2022 representing a change of -2454.74%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Operating Cash Flow: Operating Cash Flow decreased to -70 million in 2023 from -60 million in 2022 representing a change of -17.84%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -76 million in 2023 from -63 million in 2022 representing a change of -20.54%. This indicates a decrease in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation increased to 18 million in 2023 from 17 million in 2022 representing a change of 5.08%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001393434 | |||
| operating cash flow | -36559000 | -24802000 | -47.40 |
| free cash flow | -36648000 | -25544000 | -43.47 |
| capital expenditure | -89000 | -742000 | 88.01 |
| depreciation and amortization | 959000 | 956000 | 0.31 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 6641000 | 11293000 | -41.19 |
| accounts receivables | -3000 | -3686000 | 99.92 |
| accounts payables | 297000 | -2420000 | 112.27 |
| inventory | 142000 | 27000 | 425.93 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -89000 | -742000 | 88.01 |
| net cash used for investing activites | -89000 | -742000 | 88.01 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | -2196000 | 2196000 | -200.00 |
| common stock repurchased | 492000 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 4178000 | 2196000 | 90.26 |
| net change in cash | -30856000 | -23348000 | -32.16 |
| cash at end of period | 428834000 | 459690000 | -6.71 |
| cash at beginning of period | 459690000 | 483038000 | -4.83 |
Net Change in Cash: Net Change in Cash decreased to -31 million in 2024Q3 from -23 million in 2024Q2 representing a change of -32.16%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -37 million in 2024Q3 from -25 million in 2024Q2 representing a change of -47.4%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -37 million in 2024Q3 from -26 million in 2024Q2 representing a change of -43.47%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to 0 million in 2024Q3 from -1 million in 2024Q2 representing a change of 88.01%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Accounts Receivables: Accounts Receivables increased to 0 in 2024Q3 from -4 million in 2024Q2 representing a change of 99.92%. This suggests that the company is less capable of collecting payments from its customers.
Stock-Based Compensation: Stock-Based Compensation decreased to 7 million in 2024Q3 from 11 million in 2024Q2 representing a change of -41.19%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 0 million in 2024Q3 from 2 million in 2024Q2 representing a change of 112.27%. This indicates that the company has reduced its outstanding obligations to its suppliers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0.73 | 0.67 | 9.30 |
| net income per share | -1.01 | -0.83 | -22.59 |
| operating cash flow per share | -0.88 | -0.78 | -13.48 |
| free cash flow per share | -0.96 | -0.82 | -16.08 |
| cash per share | 2.45 | 1.33 | 84.33 |
| book value per share | 1.14 | 0.46 | 148.06 |
| tangible book value per share | 1.14 | 0.46 | 148.06 |
| shareholders equity per share | 1.14 | 0.46 | 148.06 |
| interest debt per share | 1.19 | 0.93 | 27.93 |
| market cap | 356030034.52 | 216018848.35 | 64.81 |
| enterprise value | 243612034.52 | 178001848.35 | 36.86 |
| pe ratio | -4.41 | -3.41 | -29.47 |
| price to sales ratio | 6.09 | 4.2 | 45.22 |
| pocfratio | -5.07 | -3.62 | -39.87 |
| pfcf ratio | -4.66 | -3.41 | -36.73 |
| pb ratio | 3.91 | 6.11 | -36.02 |
| ptb ratio | 3.91 | 6.11 | -36.02 |
| ev to sales | 4.17 | 3.46 | 20.59 |
| enterprise value over ebitda | -3.67 | -2.88 | -27.57 |
| ev to operating cash flow | -3.47 | -2.99 | -16.14 |
| ev to free cash flow | -3.19 | -2.81 | -13.54 |
| earnings yield | -0.23 | -0.29 | 22.76 |
| free cash flow yield | -0.21 | -0.29 | 26.87 |
| debt to equity | 0.92 | 1.82 | -49.64 |
| debt to assets | 0.33 | 0.43 | -23.17 |
| net debt to ebitda | 1.69 | 0.61 | 175.63 |
| current ratio | 6.66 | 4.13 | 61.18 |
| interest coverage | -7.27 | -11.2 | 35.13 |
| income quality | 0.87 | 0.84 | 3.68 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.58 | 0.63 | -7.20 |
| research and ddevelopement to revenue | 1.04 | 1.04 | 0.62 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.09 | -0.06 | -39.05 |
| capex to revenue | 0.1 | 0.07 | 44.37 |
| capex to depreciation | 2.04 | 1.76 | 15.84 |
| stock based compensation to revenue | 0.3 | 0.33 | -7.42 |
| graham number | 5.1 | 2.92 | 74.38 |
| roic | -0.38 | -0.58 | 35.06 |
| return on tangible assets | -0.32 | -0.42 | 24.60 |
| graham net net | 0.7 | 0.07 | 898.11 |
| working capital | 197339000 | 98232000 | 100.89 |
| tangible asset value | 91131000 | 35379000 | 157.59 |
| net current asset value | 71306000 | 15717000 | 353.69 |
| invested capital | 215550000 | 116130000 | 85.61 |
| average receivables | 23752000 | 21230000 | 11.88 |
| average payables | 4756000 | 4857500 | -2.09 |
| average inventory | 2139500 | 1612000 | 32.72 |
| days sales outstanding | 163.5 | 151.16 | 8.17 |
| days payables outstanding | 303.35 | 411.87 | -26.35 |
| days of inventory on hand | 159.31 | 158.7 | 0.38 |
| receivables turnover | 2.23 | 2.41 | -7.55 |
| payables turnover | 1.2 | 0.89 | 35.77 |
| inventory turnover | 2.29 | 2.3 | -0.38 |
| roe | -0.89 | -1.79 | 50.58 |
| capex per share | 0.08 | 0.05 | 57.79 |
ROE: Return on Equity (ROE) increased to -0.89 on 2023-12-31 from -1.79 on 2022-12-31, representing a change of 50.58%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -4.41 on 2023-12-31 from -3.41 on 2022-12-31, representing a change of -29.47%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 6.66 on 2023-12-31 from 4.13 on 2022-12-31, representing a change of 61.18%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.92 on 2023-12-31 from 1.82 on 2022-12-31, representing a change of -49.64%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| OCUL | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0.09 | 0.1 | -6.84 |
| net income per share | -0.22 | -0.26 | 17.22 |
| operating cash flow per share | -0.22 | -0.15 | -46.37 |
| free cash flow per share | -0.22 | -0.15 | -42.47 |
| cash per share | 2.56 | 2.77 | -7.71 |
| book value per share | 2.11 | 2.28 | -7.45 |
| tangible book value per share | 2.11 | 2.28 | -7.45 |
| shareholders equity per share | 2.11 | 2.28 | -7.45 |
| interest debt per share | 0.47 | 0.47 | -0.36 |
| market cap | 1452836794.5 | 1104393021.48 | 31.55 |
| enterprise value | 1100740794.5 | 719591021.48 | 52.97 |
| pe ratio | -9.95 | -6.31 | -57.81 |
| price to sales ratio | 94.19 | 67.17 | 40.22 |
| pocfratio | -39.74 | -44.53 | 10.75 |
| pfcf ratio | -39.64 | -43.23 | 8.31 |
| pb ratio | 4.13 | 2.92 | 41.15 |
| ptb ratio | 4.13 | 2.92 | 41.15 |
| ev to sales | 71.36 | 43.77 | 63.04 |
| enterprise value over ebitda | -34.07 | -18.16 | -87.60 |
| ev to operating cash flow | -30.11 | -29.01 | -3.77 |
| ev to free cash flow | -30.04 | -28.17 | -6.62 |
| earnings yield | -0.03 | -0.04 | 36.63 |
| free cash flow yield | -0.03 | -0.02 | -9.06 |
| debt to equity | 0.21 | 0.2 | 7.63 |
| debt to assets | 0.15 | 0.14 | 5.78 |
| net debt to ebitda | 10.9 | 9.71 | 12.22 |
| current ratio | 13.01 | 16.64 | -21.79 |
| interest coverage | -14.27 | -13.64 | -4.61 |
| income quality | 1.0 | 0.57 | 76.83 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.79 | 1.2 | -33.71 |
| research and ddevelopement to revenue | 2.4 | 1.76 | 36.86 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.0 | -0.03 | 91.86 |
| capex to revenue | 0.01 | 0.05 | -87.22 |
| capex to depreciation | 0.09 | 0.78 | -88.04 |
| stock based compensation to revenue | 0.43 | 0.69 | -37.32 |
| graham number | 3.22 | 3.68 | -12.47 |
| roic | -0.1 | -0.09 | -13.13 |
| return on tangible assets | -0.07 | -0.08 | 12.10 |
| graham net net | 1.87 | 2.08 | -9.78 |
| working capital | 436652000 | 468613000 | -6.82 |
| tangible asset value | 352021000 | 377695000 | -6.80 |
| net current asset value | 334663000 | 359189000 | -6.83 |
| invested capital | 452396000 | 485505000 | -6.82 |
| average receivables | 30233500 | 28389000 | 6.50 |
| average payables | 3845000 | 5071000 | -24.18 |
| average inventory | 2476000 | 2560500 | -3.30 |
| days sales outstanding | 176.41 | 165.49 | 6.60 |
| days payables outstanding | 230.68 | 220.02 | 4.84 |
| days of inventory on hand | 138.66 | 151.91 | -8.72 |
| receivables turnover | 0.51 | 0.54 | -6.19 |
| payables turnover | 0.39 | 0.41 | -4.62 |
| inventory turnover | 0.65 | 0.59 | 9.55 |
| roe | -0.1 | -0.12 | 10.56 |
| capex per share | 0.0 | 0.0 | -88.09 |
ROE: Return on Equity (ROE) increased to -0.10 on 2024-09-30 Q3 from -0.12 on 2024-06-30 Q2, representing a change of 10.56%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -9.95 on 2024-09-30 Q3 from -6.31 on 2024-06-30 Q2, representing a change of -57.81%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 13.01 on 2024-09-30 Q3 from 16.64 on 2024-06-30 Q2, representing a change of -21.79%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.21 on 2024-09-30 Q3 from 0.20 on 2024-06-30 Q2, representing a change of 7.63%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2025-01-17 07:00:00
BEDFORD, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to one newly hired employee. The awards were made as inducements material to the individual's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Sentiment: Positive
Publish Date: 2025-01-14 07:00:00
311 subjects enrolled across various stages of loading and randomization in SOL-R, Ocular's second registrational trial of AXPAXLI™ in wet AMD, as of January 10, 2024
Sentiment: Positive
Publish Date: 2024-12-30 12:16:51
Ocular Therapeutics' OTX-TKI implant offers a cost-effective, long-lasting alternative to gene therapies for wet AMD, showing superior duration and comparable efficacy to Regeneron's Eylea. Recent FDA approval for trial modifications and positive phase 1 results in NPDR patients enhance OTX-TKI's potential, with phase 3 data expected by Q4 2025. Financially, OCUL is strong with a $1.34bn market cap and $427mn cash, ensuring a runway of 8-9 quarters despite high R&D expenses.
Sentiment: Positive
Publish Date: 2024-12-13 07:00:00
BEDFORD, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it has agreed to grant inducement awards to one newly hired employee. The awards were made as inducements material to the individual's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Sentiment: Positive
Publish Date: 2024-12-10 07:30:00
BEDFORD, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference to be held January 13-16, 2025 in San Francisco, CA.
Sentiment: Positive
Publish Date: 2024-12-02 07:30:00
SOL-1 is the first registrational trial for AXPAXLI™ in wet AMD Topline clinical data from SOL-1 expected in Q4 2025 Active clinical trial sites enrolling patients directly into second registrational trial, SOL-R, while additional sites continue to be activated BEDFORD, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that more than 300 patients have been randomized in the SOL-1 Phase 3 trial for AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), and the trial is expected to close randomization this week.
Sentiment: Positive
Publish Date: 2024-11-26 07:30:00
BEDFORD, Mass. , Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced participation in several investor and scientific conferences being held in December.
Sentiment: Negative
Publish Date: 2024-11-14 09:41:08
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.51 per share a year ago.
Sentiment: Positive
Publish Date: 2024-11-13 07:30:00
BEDFORD, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced upcoming presentations at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV.
Sentiment: Positive
Publish Date: 2024-11-06 07:30:00
BEDFORD, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it plans to host a conference call and webcast on Thursday, November 14, 2024, at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2024.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
